Pembrolizumab in adjuvant NSCLC therapy can trigger central adrenal insufficiency with vague fatigue, nausea, and hyponatremia.
Jamie Stewart, PharmD Candidate
Advertisement
Articles by Jamie Stewart, PharmD Candidate
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Functional Cure of Hepatitis B Infections Among Patients Coinfected With HIV
2
White Bagging, Brown Bagging, and the Pharmacist Caught in the Middle
3
FDA Expands Casgevy Approval to Children as Young as 2 Years With Sickle Cell Disease or Transfusion-Dependent β-Thalassemia
4
Targeting Aldosterone at Its Source: The Arrival of Baxdrostat for Resistant Hypertension
5